Termination of the Japan Development, Co-Promotion and Manufacturing License Agreement for E3710 with Zeria Pharmaceutical Co., Ltd.
A specific event involving EA Pharma's termination of its agreement with Zeria Pharmaceutical Co., Ltd. covering the development, co-promotion and manufacturing licensing of the proton pump inhibitor E3710 in Japan.
Companies1How many companies write about this.
Threads1One company can carry more than one thread here.